Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Olema Pharmaceuticals, Inc. (OLMA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 55,110,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for women's cancers. Co. is focused on developing therapies for the treatment of breast cancer. Co.'s wholly owned, primary product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader. Co. is evaluating OP-1250 in a dose escalation and expansion trial for the treatment of ER-positive, human epidermal growth factor receptor 2-negative breast cancer.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 231,870 2,245,932 2,295,932
Total Buy Value $0 $3,031,280 $22,849,650 $22,849,650
Total People Bought 0 2 3 5
Total Buy Transactions 0 2 4 7
Total Shares Sold 65,000 257,333 392,533 392,533
Total Sell Value $726,959 $3,376,319 $4,856,341 $4,856,341
Total People Sold 1 5 5 5
Total Sell Transactions 4 18 29 29
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 119
  Page 4 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bohen Sean PRESIDENT AND CEO   •       •      –    2021-09-01 4 AS $30.05 $26,174 D/D (871) 54,274     -
   Bohen Sean PRESIDENT AND CEO   •       •      –    2021-09-01 4 OE $4.82 $4,202 D/D 871 55,145     -
   Harmon Cyrus CHIEF TECHNOLOGY OFFICER   •       •      –    2021-08-19 4 AS $24.97 $299,640 D/D (12,000) 1,075,546     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-08-10 4 AS $25.70 $134,979 D/D (5,251) 1,790     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-08-10 4 OE $2.06 $10,838 D/D 5,251 7,041     -
   Harmon Cyrus CHIEF TECHNOLOGY OFFICER   •       •      –    2021-07-20 4 AS $25.63 $105,672 D/D (4,123) 1,087,546     -
   Harmon Cyrus CHIEF TECHNOLOGY OFFICER   •       •      –    2021-07-19 4 AS $24.83 $195,586 D/D (7,877) 1,091,669     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-07-12 4 AS $26.33 $139,191 D/D (5,251) 1,790     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-07-12 4 OE $2.06 $10,838 D/D 5,251 7,041     -
   Harmon Cyrus CHIEF TECHNOLOGY OFFICER   •       •      –    2021-06-18 4 AS $24.54 $297,626 D/D (12,000) 1,099,546     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-06-10 4 AS $28.30 $156,071 D/D (5,251) 1,790     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-06-10 4 OE $2.06 $10,838 D/D 5,251 7,041     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-05-18 4 AS $24.03 $1,394,769 D/D (57,763) 1,790     -
   Horn Kinney CHIEF BUSINESS OFFICER   •       –      –    2021-05-18 4 OE $2.06 $119,223 D/D 57,763 59,553     -
   Lampert Mark N 10% Owner   –       –       •   2021-03-31 4 A $0.00 $0 I/I 99,556 99,556     -
   Wellington Biomedical Innovation Master Investors 10% Owner   –       –       •   2020-11-23 4 A $0.00 $0 D/D 1,725,406 1,725,406     -
   Graham G. Walmsley Director   –       •      –    2020-11-23 4 B $19.00 $22,040,000 I/I 1,160,000 1,160,000 2.1     -
   Graham G. Walmsley Director   –       •      –    2020-11-23 4 A $0.00 $0 I/I 2,583,875 1,183,114     -
   Mccormick Frank Director   –       •      –    2020-11-23 4 A $0.00 $0 I/I 66,326 84,260     -
   Mccormick Frank Director   –       •      –    2020-11-23 4 A $0.00 $0 D/D 152,891 191,113     -
   Myles David C. Chief Development Officer   •       –      –    2020-11-23 4 A $0.00 $0 I/I 167,677 154,846     -
   Cormorant Private Healthcare Fund Iii Lp 10% Owner   –       –       •   2020-11-23 4 B $19.00 $8,075,000 I/I 425,000 3,270,544 1.5     -
   Cormorant Private Healthcare Fund Iii Lp 10% Owner   –       –       •   2020-11-23 4 A $0.00 $0 I/I 2,845,544 2,845,544     -
   Kushner Peter J. Chief Scientific Officer   •       –      –    2020-11-23 4 A $0.00 $0 D/D 358,920 1,431,672     -
   Rappaport Andrew Director   –       •      –    2020-11-23 4 A $0.00 $0 I/I 448,556 481,014     -

  119 Records found
  1  2  3  4  5   
  Page 4 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed